Humanin vs NMN
A side-by-side research comparison of Humanin and NMN across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Humanin | NMN |
|---|---|---|
| Full name | Humanin (HN) Mitochondrial-Derived Peptide | Nicotinamide Mononucleotide |
| Category | Anti-Aging | Anti-Aging |
| Status | Research compound | Dietary compound (research ongoing) |
| Mechanism | Binds IGFBP-3, BAX, and trimeric receptor (CNTFR/WSX-1/gp130) to activate STAT3. Inhibits mitochondrial apoptosis and provides neuroprotection. | NMN is converted to NAD+ via the NAD+ salvage pathway (through NMNAT enzymes). Higher NAD+ supports sirtuin activity, PARP-mediated DNA repair, and mitochondrial energy metabolism. |
| Molecular weight | 2,687 Da | 334.22 Da |
| Half-life | 4-6 hours | Short; rapidly taken up and converted to NAD+ |
| Bioavailability | Moderate (SubQ) | Oral absorption reported; sublingual and injectable forms also used |
| Typical dose | 1-5 mg | 250-1000 mg per day |
| Frequency | 3-5x per week | Once daily |
| Route | Subcutaneous | Oral (capsule/sublingual) |
Humanin reported benefits
- Neuroprotection against amyloid-beta
- Anti-apoptotic
- Improved insulin sensitivity
- Cardioprotection
- Cellular stress resistance
NMN reported benefits
- Raises cellular NAD+ levels
- Supports mitochondrial energy production
- Promotes DNA repair via sirtuins/PARPs
- Studied for metabolic and vascular health
Related comparisons
Research and educational reference only. Not medical advice.